Company Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
33.39 USD -2.79% Intraday chart for Protagonist Therapeutics, Inc. -4.05% +45.62%

Business Summary

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

Number of employees: 124

Sales per Business

USD in Million2022Weight2023Weight Delta
Peptide-based Therapeutics
100.0 %
27 100.0 % 60 100.0 % +125.73%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
27 100.0 % 60 100.0 % +125.73%

Managers

Managers TitleAgeSince
Chief Executive Officer 67 08-11-30
Director of Finance/CFO 50 22-04-17
Chief Tech/Sci/R&D Officer - 17-06-30
Chief Tech/Sci/R&D Officer 69 18-05-23
Chief Tech/Sci/R&D Officer 65 22-11-06
General Counsel - -
Human Resources Officer - -
Corporate Officer/Principal 66 19-01-16
Corporate Officer/Principal - 16-12-31
Corporate Officer/Principal 52 18-08-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 74 17-06-07
Chairman 69 09-01-31
Director/Board Member 61 23-10-25
Chief Executive Officer 67 08-11-30
Director/Board Member 74 20-08-11
Director/Board Member 67 16-06-30
Director/Board Member 49 18-05-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 58,652,133 56,866,179 ( 96.96 %) 0 96.96 %

Shareholders

NameEquities%Valuation
Farallon Capital Management LLC
9.785 %
5,738,973 9.785 % 162 M $
RTW Investments LP
9.063 %
5,315,514 9.063 % 150 M $
BlackRock Advisors LLC
8.905 %
5,222,683 8.905 % 147 M $
BVF, Inc.
6.404 %
3,755,990 6.404 % 106 M $
3,272,485 5.579 % 92 M $
Vanguard Fiduciary Trust Co.
5.444 %
3,192,971 5.444 % 90 M $
Johnson & Johnson Innovation - JJDC, Inc.
4.176 %
2,449,183 4.176 % 69 M $
Adage Capital Partners GP LLC
3.783 %
2,218,868 3.783 % 62 M $
Morgan Stanley Investment Management, Inc.
3.205 %
1,879,878 3.205 % 53 M $
Cowen & Co. LLC
2.656 %
1,557,636 2.656 % 44 M $

Company contact information

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard Suite 140

94560-1160, Newark

+

http://www.protagonist-inc.com
address Protagonist Therapeutics, Inc.(PTGX)
  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. Company Protagonist Therapeutics, Inc.